公开(公告)号：US11958865B1

公开(公告)日：2024-04-16

申请号：US18467162

申请日：2023-09-14

Applicant: H. Lundbeck A/S

Inventor： Thomas Jensen ,  Thomas Andersen ,  Mikkel Jessing ,  Jacob Nielsen ,  Henrik Daver ,  Christopher Richard Jones

IPC: C07D498/22

CPC classification number: C07D498/22 ,  C07B2200/05 ,  C07D498/22 ,  C07B2200/05

Abstract: The present invention is directed to compounds of formula IIa




These compounds are considered useful for the treatment of diseases associated with leucine-rich repeat kinase 2 (LRRK2) such as Parkinson's disease. Furthermore, the invention relates to pharmaceutical compositions comprising said compounds.

公开(公告)号：US20230144725A1

公开(公告)日：2023-05-11

申请号：US18049802

申请日：2022-10-26

Applicant: H. Lundbeck A/S ,  Vernalis (R&D) Limited

Inventor： Thomas Jensen ,  Mikkel Jessing ,  Wanwan YU ,  David Rodriguez Diaz ,  Jacob Nielsen ,  Christopher Richard Jones ,  Thomas Andersen ,  Mikkel Fog Jacobsen

IPC: C07D498/22

CPC classification number: C07D498/22 ,  C07B2200/05

Abstract: The present invention is directed to compounds of formula I




The compounds are considered useful for the treatment of diseases associated with LRRK2 such as Parkinson's disease.

公开(公告)号：US20240343741A1

公开(公告)日：2024-10-17

申请号：US18583002

申请日：2024-02-21

Applicant: H. Lundbeck A/S

Inventor： Thomas Jensen ,  Thomas Andersen ,  Mikkel Jessing ,  Jacob Nielsen ,  Henrik Daver ,  Christopher Richard Jones

IPC: C07D498/22

CPC classification number: C07D498/22 ,  C07B2200/05

Abstract: The present invention is directed to compounds of formula IIa




These compounds are considered useful for the treatment of diseases associated with leucine-rich repeat kinase 2 (LRRK2) such as Parkinson's disease. Furthermore, the invention relates to pharmaceutical compositions comprising said compounds.

公开(公告)号：US11993612B2

公开(公告)日：2024-05-28

申请号：US18331289

申请日：2023-06-08

Applicant: H. Lundbeck A/S

Inventor： Thomas Jensen ,  Mikkel Jessing ,  Wanwan Yu ,  David Rodriguez Diaz ,  Jacob Nielsen ,  Christopher Richard Jones ,  Thomas Andersen ,  Mikkel Fog Jacobsen

IPC: C07D498/22

CPC classification number: C07D498/22 ,  C07B2200/05

Abstract: The present invention is directed to compounds of formula I




The compounds are considered useful for the treatment of diseases associated with LRRK2 such as Parkinson's disease.

公开(公告)号：US20230416272A1

公开(公告)日：2023-12-28

申请号：US18331289

申请日：2023-06-08

Applicant: H. Lundbeck A/S ,  Vernalis (R&D) Limited

Inventor： Thomas Jensen ,  Mikkel Jessing ,  Wanwan Yu ,  David Rodriguez Diaz ,  Jacob Nielsen ,  Christopher Richard Jones ,  Thomas Andersen ,  Mikkel Fog Jacobsen

IPC: C07D498/22

CPC classification number: C07D498/22 ,  C07B2200/05

Abstract: The present invention is directed to compounds of formula I




The compounds are considered useful for the treatment of diseases associated with LRRK2 such as Parkinson's disease.

公开(公告)号：US11780851B2

公开(公告)日：2023-10-10

申请号：US18049802

申请日：2022-10-26

Applicant: H. Lundbeck A/S ,  Vernalis (R&D) Limited

Inventor： Thomas Jensen ,  Mikkel Jessing ,  Wanwan Yu ,  David Rodriguez Diaz ,  Jacob Nielsen ,  Christopher Richard Jones ,  Thomas Andersen ,  Mikkel Fog Jacobsen

IPC: C07D498/22

CPC classification number: C07D498/22 ,  C07B2200/05

Abstract: The present invention is directed to compounds of formula I




The compounds are considered useful for the treatment of diseases associated with LRRK2 such as Parkinson's disease.